Image pharmaphorum Editor News Glenmark and Lotus partner on allergic rhinitis spray The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. News Sugemalimab plus chemo boosts lung cancer survival, trial re... Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. News BioTuring enters collaboration to enable detailed single-cel... Research into single-cell sequencing has been boosted with Single Cell Discoveries and BioTuring joining forces to refine the process. News Poolbeg licences candidate for broad-spectrum respiratory in... Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus. Load more results
News Glenmark and Lotus partner on allergic rhinitis spray The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces.
News Sugemalimab plus chemo boosts lung cancer survival, trial re... Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial.
News BioTuring enters collaboration to enable detailed single-cel... Research into single-cell sequencing has been boosted with Single Cell Discoveries and BioTuring joining forces to refine the process.
News Poolbeg licences candidate for broad-spectrum respiratory in... Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
